1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Personalized Vaccine
1.2.3 Off-the-shelf Neovaccines
1.3 Market by Application
1.3.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neoantigen Cancer Vaccine Market Perspective (2017-2028)
2.2 Neoantigen Cancer Vaccine Growth Trends by Region
2.2.1 Neoantigen Cancer Vaccine Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neoantigen Cancer Vaccine Historic Market Size by Region (2017-2022)
2.2.3 Neoantigen Cancer Vaccine Forecasted Market Size by Region (2023-2028)
2.3 Neoantigen Cancer Vaccine Market Dynamics
2.3.1 Neoantigen Cancer Vaccine Industry Trends
2.3.2 Neoantigen Cancer Vaccine Market Drivers
2.3.3 Neoantigen Cancer Vaccine Market Challenges
2.3.4 Neoantigen Cancer Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Cancer Vaccine Players by Revenue
3.1.1 Global Top Neoantigen Cancer Vaccine Players by Revenue (2017-2022)
3.1.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Players (2017-2022)
3.2 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neoantigen Cancer Vaccine Revenue
3.4 Global Neoantigen Cancer Vaccine Market Concentration Ratio
3.4.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2021
3.5 Neoantigen Cancer Vaccine Key Players Head office and Area Served
3.6 Key Players Neoantigen Cancer Vaccine Product Solution and Service
3.7 Date of Enter into Neoantigen Cancer Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neoantigen Cancer Vaccine Breakdown Data by Type
4.1 Global Neoantigen Cancer Vaccine Historic Market Size by Type (2017-2022)
4.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2023-2028)
5 Neoantigen Cancer Vaccine Breakdown Data by Application
5.1 Global Neoantigen Cancer Vaccine Historic Market Size by Application (2017-2022)
5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neoantigen Cancer Vaccine Market Size (2017-2028)
6.2 North America Neoantigen Cancer Vaccine Market Size by Type
6.2.1 North America Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
6.2.2 North America Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
6.2.3 North America Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
6.3 North America Neoantigen Cancer Vaccine Market Size by Application
6.3.1 North America Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
6.3.2 North America Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
6.3.3 North America Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
6.4 North America Neoantigen Cancer Vaccine Market Size by Country
6.4.1 North America Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
6.4.2 North America Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Neoantigen Cancer Vaccine Market Size (2017-2028)
7.2 Europe Neoantigen Cancer Vaccine Market Size by Type
7.2.1 Europe Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
7.2.2 Europe Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
7.2.3 Europe Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
7.3 Europe Neoantigen Cancer Vaccine Market Size by Application
7.3.1 Europe Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
7.3.2 Europe Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
7.3.3 Europe Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
7.4 Europe Neoantigen Cancer Vaccine Market Size by Country
7.4.1 Europe Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
7.4.2 Europe Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size (2017-2028)
8.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type
8.2.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
8.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application
8.3.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
8.4 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region
8.4.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neoantigen Cancer Vaccine Market Size (2017-2028)
9.2 Latin America Neoantigen Cancer Vaccine Market Size by Type
9.2.1 Latin America Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
9.2.2 Latin America Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
9.2.3 Latin America Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
9.3 Latin America Neoantigen Cancer Vaccine Market Size by Application
9.3.1 Latin America Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
9.3.2 Latin America Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
9.3.3 Latin America Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
9.4 Latin America Neoantigen Cancer Vaccine Market Size by Country
9.4.1 Latin America Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
9.4.2 Latin America Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size (2017-2028)
10.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type
10.2.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
10.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application
10.3.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
10.4 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country
10.4.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Neoantigen Cancer Vaccine Introduction
11.1.4 Roche Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Medimmune
11.2.1 Medimmune Company Details
11.2.2 Medimmune Business Overview
11.2.3 Medimmune Neoantigen Cancer Vaccine Introduction
11.2.4 Medimmune Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.2.5 Medimmune Recent Developments
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Neoantigen Cancer Vaccine Introduction
11.3.4 Merck Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.3.5 Merck Recent Developments
11.4 Advaxis
11.4.1 Advaxis Company Details
11.4.2 Advaxis Business Overview
11.4.3 Advaxis Neoantigen Cancer Vaccine Introduction
11.4.4 Advaxis Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.4.5 Advaxis Recent Developments
11.5 Agenus
11.5.1 Agenus Company Details
11.5.2 Agenus Business Overview
11.5.3 Agenus Neoantigen Cancer Vaccine Introduction
11.5.4 Agenus Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.5.5 Agenus Recent Developments
11.6 Genocea
11.6.1 Genocea Company Details
11.6.2 Genocea Business Overview
11.6.3 Genocea Neoantigen Cancer Vaccine Introduction
11.6.4 Genocea Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.6.5 Genocea Recent Developments
11.7 Gritstone Oncology
11.7.1 Gritstone Oncology Company Details
11.7.2 Gritstone Oncology Business Overview
11.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Introduction
11.7.4 Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.7.5 Gritstone Oncology Recent Developments
11.8 Neon Therapeutics
11.8.1 Neon Therapeutics Company Details
11.8.2 Neon Therapeutics Business Overview
11.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Introduction
11.8.4 Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.8.5 Neon Therapeutics Recent Developments
11.9 Nouscom
11.9.1 Nouscom Company Details
11.9.2 Nouscom Business Overview
11.9.3 Nouscom Neoantigen Cancer Vaccine Introduction
11.9.4 Nouscom Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.9.5 Nouscom Recent Developments
11.10 OSE Immunotherapeutics
11.10.1 OSE Immunotherapeutics Company Details
11.10.2 OSE Immunotherapeutics Business Overview
11.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Introduction
11.10.4 OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.10.5 OSE Immunotherapeutics Recent Developments
11.11 Medigene
11.11.1 Medigene Company Details
11.11.2 Medigene Business Overview
11.11.3 Medigene Neoantigen Cancer Vaccine Introduction
11.11.4 Medigene Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.11.5 Medigene Recent Developments
11.12 Vaccibody
11.12.1 Vaccibody Company Details
11.12.2 Vaccibody Business Overview
11.12.3 Vaccibody Neoantigen Cancer Vaccine Introduction
11.12.4 Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.12.5 Vaccibody Recent Developments
11.13 Brightpath Biotherapeutics
11.13.1 Brightpath Biotherapeutics Company Details
11.13.2 Brightpath Biotherapeutics Business Overview
11.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Introduction
11.13.4 Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.13.5 Brightpath Biotherapeutics Recent Developments
11.14 Geneos Therapeutics
11.14.1 Geneos Therapeutics Company Details
11.14.2 Geneos Therapeutics Business Overview
11.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Introduction
11.14.4 Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.14.5 Geneos Therapeutics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
